来自 Maksym Misichenko · Nasdaq ·
AI智能体对这条新闻的看法
Despite a potential stock split, Eli Lilly's extreme valuation (55-65x forward earnings) and intense competition from Novo Nordisk and oral-tablet entrants pose significant risks. The panel is divided on whether Lilly's manufacturing investments will yield the expected volume surge, with some expressing concern about margin compression and others highlighting the potential of Mounjaro/Zepbound's superior efficacy.
风险: Margin compression due to intense competition and potential shifts in FDA requirements for cardiovascular outcomes.
机会: The potential of Mounjaro/Zepbound's superior weight loss efficacy and Lilly's ability to scale production while competitors struggle with the supply chain complexity of biologics.
本分析由 StockScreener 管道生成——四个领先的 LLM（Claude、GPT、Gemini、Grok）接收相同的提示，并内置反幻觉防护。 阅读方法论 →
最近，市场上的股票分拆活动频繁，从科技巨头英伟达到休闲快餐连锁餐厅奇波特墨西哥厨房，多家公司都宣布了股票分拆计划。这发生在这些股票在近年来飙升之后，其中许多股票的价格都达到了数千美元。公司进行股票分拆是为了降低每股的股价，使其更易于更广泛的投资者承受。
投资者寻找这些机会的原因有两个。首先，这使得买家能够在不依赖于零股的情况下，对一家特定的公司进行小额投资。其次，股票分拆通常表明公司对其未来充满信心，认为在新的较低水平上，股票可能会再次起飞。
您如何识别潜在的股票分拆候选者？当一只股票随着时间的推移而上涨，并最终以数百美元（或更多）的价格交易时，一家公司可能会考虑进行分拆。今天属于这一类别的制药公司是礼来制药（纽约证券交易所代码：LLY）。
该公司今年的股价已上涨超过 50%，突破了 900 美元大关。礼来公司是否很快会宣布分拆？
首先，重要的是要考虑礼来公司的股价为何大幅上涨。该公司拥有多元化的药物产品组合，专注于免疫学、糖尿病、癌症等领域。随着时间的推移，这些治疗方法帮助礼来公司将收入和净收入增长到数十亿美元的规模。
但真正推动近期收入增长和股价表现的产品是礼来公司的减肥药物。该公司销售 Zepbound，专门用于此适应症，以及 Mounjaro，虽然官方获批用于治疗 2 型糖尿病，但医生经常将其开用于控制体重。
Mounjaro 在 2022 年获得批准后，去年收入飙升至超过 51 亿美元的“现象级”水平。而 Zepbound 在去年底获得监管部门批准，其第一个完整季度带来了 5.17 亿美元的收入——这意味着它正稳步发展成为现象级产品。
以下两点表明这些药物未来可能继续大幅提高收入。
Zepbound 最近在治疗阻塞性睡眠呼吸暂停的 3 期试验中取得了积极结果，并且礼来公司已将该药物提交给美国食品药品监督管理局，以寻求在肥胖成人中获得批准用于该适应症。在这里获得监管部门的批准将对礼来公司来说是好消息，因为医疗保险只覆盖减肥药物，如果它们也获得批准用于其他健康益处，则会获得覆盖。而医疗保险的覆盖是药物普及的关键因素。
然而，礼来公司的减肥药物——以及竞争对手诺和泰制药的减肥药物——的需求超过了供应，这两家公司不得不加大生产基础设施建设，以努力跟上。自 2020 年以来，礼来公司已承诺投资超过 180 亿美元用于生产投资，这将有助于其从这些高需求药物中产生更多的收入。
现在让我们考虑一下礼来公司潜在股票分拆的案例。该公司已完成四次 2 比 1 的股票分拆，最近一次是在 25 多年前。这些分拆发生在股价大幅上涨之后，当时股价约为 100 美元——与今天的水平相去甚远。这表明礼来公司在股价大幅上涨后，一直愿意进行股票分拆，尽管最近一次分拆已经过去很久了。
礼来公司现在推出分拆的优势在于，这将在增长强劲时向更多投资者开放股票——并且这种增长很容易推动股价进一步上涨。正如我上面提到的，礼来公司的减肥药物已经起飞，并且公司的生产能力提升以及 Zepbound 的新适应症都可能增加销售潜力。
此外，礼来公司还在 3 期试验中研究其他减肥候选药物。如果一切顺利，这些药物未来可能代表更多的增长。
最后，900 美元或更高的价格可能会阻止一些投资者按下买入按钮。在某些情况下，他们可能希望以较小的投资购买这家制药公司，而他们的经纪商可能不提供零股。接近 1000 美元的价格对那些可能认为该股价格过高（即使估值合理）的投资者来说，代表着一种心理障碍。
现在或在不久的将来分拆其股票将对礼来公司来说是一个好主意。当然，无法 100% 准确地预测该公司是否会宣布分拆。但好消息是，即使礼来公司没有这样做，由于公司的良好历史业绩和未来前景，这仍然是一家值得长期持有和购买的股票。
在购买礼来制药股票之前，请考虑以下事项：
Motley Fool Stock Advisor 分析师团队刚刚确定他们认为投资者现在应该购买的 10 支最佳股票……而礼来制药不是其中之一。这些股票可能会在未来几年产生巨大的回报。
请考虑英伟达在 2005 年 4 月 15 日被列入此名单时的情况……如果您当时投资了 1000 美元，您将拥有 774,526 美元！*
Stock Advisor 为投资者提供易于遵循的成功蓝图，包括关于如何构建投资组合的指导、分析师的定期更新以及每月选择两只新的股票。自 2002 年以来，Stock Advisor 服务已 超过四倍于标准普尔 500 指数。
截至 2024 年 6 月 24 日的 Stock Advisor 回报*
Adria Cimino 对所提及的任何股票都没有持仓。Motley Fool 持有并推荐奇波特墨西哥厨房和英伟达。Motley Fool 还推荐诺和泰制药。Motley Fool 有披露政策。
本文中的观点和意见是作者的观点和意见，不一定代表纳斯达克公司的观点。
四大领先AI模型讨论这篇文章
"A stock split would not mitigate Lilly's core risks of supply bottlenecks and pipeline concentration."
The article frames an LLY split as a logical next step after the share price topped $900 on Mounjaro/Zepbound momentum, but splits are cosmetic and have no bearing on cash flows or competitive position. Lilly last split in 1999; its current manufacturing build-out of $18B+ faces multi-year lead times while Novo Nordisk and compounding pharmacies erode share. Medicare coverage hinges on additional indications that remain unapproved, and any delay compresses near-term revenue visibility far more than a lower nominal price would expand the buyer base.
Retail inflows after a split have historically lifted trading volume and short-term momentum even when fundamentals are unchanged, potentially extending LLY's run if sentiment stays euphoric.
"A stock split is a marketing event, not a catalyst; the real question is whether LLY's 60x forward multiple can be sustained if weight-loss drug growth moderates or manufacturing ramps disappoint."
The article conflates two separate questions: whether LLY will split (plausible, given history and $900 price), and whether that split signals bullish momentum. The split itself is cosmetic—it doesn't change market cap or fundamentals. What matters is whether Mounjaro/Zepbound growth justifies LLY's current valuation. At $900/share with ~$36B market cap, LLY trades at roughly 60x forward earnings on a pharma stock—well above historical norms even for high-growth biotech. Supply constraints are real but temporary; manufacturing ramps are capital-intensive and margin-dilutive. The article glosses over execution risk: can Lilly actually scale production without quality issues? Can Zepbound's sleep apnea indication move Medicare coverage needle meaningfully? These aren't rhetorical—they're the actual valuation drivers, not the split announcement.
If Zepbound gains Medicare coverage for sleep apnea and Lilly's pipeline candidates succeed in phase 3, the obesity market addressable size could justify current multiples—and a split could genuinely broaden retail participation, driving further re-rating.
"The obsession with a potential stock split obscures the critical risk that LLY's current 60x forward P/E multiple is unsustainable if manufacturing bottlenecks persist or pricing power erodes."
Focusing on a potential LLY stock split is a distraction from the real story: the extreme valuation gap. Trading at roughly 60x forward earnings, Eli Lilly is priced for perfection, assuming flawless execution on manufacturing capacity and continued dominance in the GLP-1 space. While a split might improve retail liquidity, it does nothing to address the fundamental risk of margin compression as competition from Novo Nordisk and oral-tablet entrants intensifies. Investors should ignore the 'split' narrative and focus on the $18 billion in capital expenditures; if those manufacturing investments don't yield the expected volume surge, the stock's premium multiple will face a sharp, painful correction.
A split could catalyze inclusion in the Dow Jones Industrial Average, forcing massive inflows from index funds that would sustain the current premium despite the high P/E.
"Stock splits are cosmetic; the real driver is Lilly's drug demand, coverage, and manufacturing execution."
Today's chatter about Eli Lilly near $900 sparking a potential stock split misses the bigger risk: a split is cosmetic, not a catalyst. Lilly's upside remains tied to its weight-loss drugs (Mounjaro, Zepbound) and the durability of payer coverage, not to a share-price haircut. The piece understates key headwinds: potential competition from Novo Nordisk, pricing/policy risk in Medicare, and the fragility of obesity indications' commercial uptake even as manufacturing ramps. A split could improve liquidity or attract retail buyers, but it won't solve demand or margin questions if growth slows or supply constraints bite. Valuation already reflects much of the good news.
A counterpoint: stock splits have historically generated little durable alpha; in Lilly's case, a split might merely boost short-term retail demand and volatility around the announcement, with no guarantee of multiple expansion if earnings growth stalls.
"Claude's market cap figure is off by an order of magnitude, distorting the multiple used to argue overvaluation."
Claude's 60x forward earnings claim relies on a flawed ~$36B market cap at $900/share. Lilly has roughly 950 million shares outstanding, placing market cap above $850B and the multiple nearer 55-65x depending on 2025 EPS forecasts. This arithmetic slip doesn't salvage the split narrative but shows how sloppy valuation anchors can exaggerate perceived premium versus history, especially when supply ramps and Novo competition already cap upside.
"The split debate obscures that LLY's valuation assumes sustained monopoly pricing in GLP-1s, which Novo's oral formulation directly threatens."
Grok's correction on market cap is valid, but it actually strengthens Claude's valuation concern: $850B+ at 55-65x forward earnings is *worse* than stated, not better. Nobody's addressed the elephant: Novo's oral semaglutide (Rybelsus) already approved, cheaper, easier to manufacture. If Novo captures 30-40% share within 18 months, LLY's $18B capex becomes stranded. A split masks this competitive cliff.
"Superior clinical efficacy of tirzepatide creates a defensive moat that justifies the current premium despite manufacturing risks."
Claude, your focus on oral semaglutide misses the clinical reality: tirzepatide (Mounjaro/Zepbound) consistently demonstrates superior weight loss efficacy in head-to-head trials. The market isn't just buying capacity; it's buying the best-in-class molecule. The risk isn't Novo's oral drug, it's the 'surrogate endpoint' trap. If the FDA shifts requirements for cardiovascular outcomes, Lilly’s $18B capex is a moat, not a liability, because they can scale production while competitors struggle with the supply chain complexity of biologics.
"Payer-driven price realization and ongoing competition are the real tests for Lilly's multiple, not capex timing or split chatter."
Claude, the missing link isn’t just capex or new indications—it's the payer and competitive dynamic. Even with a green light on obesity indications, actual net price realization may be eroded by discounting, rebates, and step therapy, especially if Novo expands its share or oral entrants steal switching behavior. That margin risk matters more than the timing of a capital build, and it could keep Lilly from sustaining a 55-65x forward multiple as growth decelerates.
Despite a potential stock split, Eli Lilly's extreme valuation (55-65x forward earnings) and intense competition from Novo Nordisk and oral-tablet entrants pose significant risks. The panel is divided on whether Lilly's manufacturing investments will yield the expected volume surge, with some expressing concern about margin compression and others highlighting the potential of Mounjaro/Zepbound's superior efficacy.
The potential of Mounjaro/Zepbound's superior weight loss efficacy and Lilly's ability to scale production while competitors struggle with the supply chain complexity of biologics.
Margin compression due to intense competition and potential shifts in FDA requirements for cardiovascular outcomes.